Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients

Table 6 Patients’ characteristics

	Age	Gender	Tumor size (mm)	CEA	CA 19-9	T	N	LNR	Margin (mm)	Differ	Vasc invas	G
LongS 1	70	F	50	8	52.3	3	1	1/57	2	W	No	IIB
LongS 2	70	M	25	2.1	202.56	3	0	0/21	1	M-P	No	IIA
LongS 3	63	M	35	2	200	4	0	0/16	3	M	Vein	III
LongS 4	66	F	50	1.1	1007	3	1	8/65	0	W-M	Vein	IIB
LongS 5	59	M	40	NA	NA	4	1	4/39	3	W-M	No	III
LongS 6	76	M	40	1.8	43.2	3	1	3/25	2	P	Vein	IIB
LongS 7	67	F	60	3.6	1626	3	1	4/43	3	M	No	IIB
LongS 8	69	F	25	1.4	220.4	3	0	0/16	3	M	No	IIA
ShortS 1	47	M	40	NA	112	3	1	6/64	2	P	No	IIB
ShortS 2	65	M	30	144	97.4	3	1	5/83	2	P	No	IIB
ShortS 3	78	F	30	3.6	250	3	1	NA	2	M	No	IIB
ShortS 4	72	F	35	2	13	3	1	NA	0	M-P	No	IIB
ShortS 5	82	F	25	NA	178	3	0	0/18	0	W	Vein	IIA
ShortS 6	49	F	30	2.3	451.5	3	1	6/42	1	P	Vein	IIB
ShortS 7	62	M	70	4.5	293.7	4	1	1/36	0	W	Vein	III
ShortS 8	60	M	40	4.2	916	3	1	18/33	0	Coll	Vein	IIB
ShortS 9	61	F	30	4.7	246.4	3	1	2/38	0	M	Vein	IIB

Seventeen samples from 17 patients with PA: 8 patients were classified as long-term survival patients (>3 years), while the 9 others had a short-term survival (<1 year). There was no significant difference in terms of T stage (p = 0.453), N+ status (p = 0.2), differentiation (p = 0.481), CA 19-9 (p = 0.236), or CEA (p = 0.322). There was a significantly larger resection margin in long-term survivors (2.13 mm vs 0.78 mm; p = 0.018). LongS long-term survival patients, ShortS short-term survival patients, CEA carcinoembryonic antigen, NA not available, CA 19-9 carbohydrate antigen 19-9. T and N describing the tumor/node/metastasis: T tumor, N lymph nodes; LNR lymph node ratio, Differ differentiation, W well-differentiated, P poorly differentiated, M moderately differentiated, Coll colloid, Vasc invas vascular invasion, G grading

ISSN: 1741-7015